Lucid Diagnostics' EsoGuard(R) now fully reimbursed by Medicare nationwide
Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission
PAVmed engaged with FDA on PortIO and Octeris
Conference call and webcast to be held today, November 13, at 8:30 AM EST
NEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. $(PAVM)$ ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the third quarter ended September 30, 2026.
Conference Call and Webcast
The webcast will take place on Friday, November 13, 2026, at 8:30 AM EST and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
Business Update Highlights
"We're very encouraged by developments across the PAVmed portfolio," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone. As Lucid's largest common shareholder, PAVmed stands to benefit directly from Lucid's substantial near-term revenue opportunity. Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission. We are also now actively engaged with FDA on both PortIO and Octeris. We believe this progress puts PAVmed in a strong position to create real long-term shareholder value."
Highlights from the third quarter and recent weeks:
-- Lucid Diagnostics:
-- Began receiving payments from Medicare for the
EsoGuard(R) Esophageal DNA Test in October. Lucid is submitting
Medicare claims for tests performed at its Texas laboratory to
Novitas, the Medicare Administrative Contractor (MAC) with
jurisdiction over that laboratory, and is receiving payments at
EsoGuard's established Clinical Laboratory Fee Schedule rate.
-- Focused commercial efforts on expanding EsoGuard access among
at-risk Medicare beneficiaries, who represent approximately 50% of
the 30 million patients recommended for esophageal precancer
testing by professional society guidelines.
-- Announced publication of an 11,991-patient real-world EsoGuard
study in the peer-reviewed journal Diagnostics, the largest
peer-reviewed study of nonendoscopic esophageal precancer testing
to date, demonstrating the efficiency and scalability of the
EsoCheck(R) Esophageal Cell Collection Device.
-- Performed 2,871 EsoGuard tests and recognized revenue of $1.2
million in 3Q26. October was a record month for EsoGuard test
volume, with more than 1,800 tests.
-- Veris Health:
-- Monthly patient enrollment at OSU-The James grew throughout the
quarter, nearly doubling from July to September, as the commercial
phase of the strategic engagement continued to accelerate and the
clinical rollout went live across most departments.
-- Achieved design freeze for the implantable physiological monitor
and, in October, initiated the 90-day GLP animal study, keeping
the device on track for an early 2027 FDA 510(k) submission.
-- PortIO:
-- Held an initial meeting with FDA on PortIO in late October, to be
followed by an in-person pre-submission meeting in January 2027
focused on the device's regulatory pathway.
-- Octeris:
-- Completed Octeris' next-generation multimodal endoscopic imaging
probe, which is ready for clinical testing. Octeris expects to
submit its initial FDA pre-submission package this month, with
enrollment in the University of North Carolina clinical validation
study expected to begin in January 2027.
Preliminary Financial Results:
-- For the three months ended September 30, 2026, operating expenses were
approximately $6.8 million, which included stock-based compensation
expenses of $1.0 million. As shown below and for the purpose of
illustrating the effect of stock-based compensation and other non-cash
income and expenses on the Company's financial results, the Company's
non-GAAP adjusted net loss was approximately $1.2 million or $(0.19) per
common share.
-- PAVmed had cash and cash equivalents of $8.9 million, including
restricted cash of $5.3 million, as of September 30, 2026, compared to
cash and cash equivalents of $1.5 million, including $0.3 million of
restricted cash, as of December 31, 2025.
PAVmed Non-GAAP Measures
-- To supplement our financial results presented in accordance with U.S.
generally accepted accounting principles (GAAP), management provides
certain non-GAAP financial measures of the Company's financial results.
These non-GAAP financial measures include net loss before interest, taxes,
depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which
further adjusts EBITDA for stock-based compensation expense, loss on the
issuance or modification of convertible securities, the periodic change
in fair value of convertible securities, and loss on debt extinguishment.
The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted
loss are not recognized terms under U.S. GAAP.
-- Non-GAAP financial measures are presented with the intent of providing
greater transparency to the information used by us in our financial
performance analysis and operational decision-making. We believe these
non-GAAP financial measures provide meaningful information to assist
investors, shareholders, and other readers of our financial statements in
making comparisons to our historical financial results and analyzing the
underlying performance of our results of operations. These non-GAAP
financial measures are not intended to be, and should not be, a
substitute for, considered superior to, considered separately from, or as
an alternative to, the most directly comparable GAAP financial measures.
-- Non-GAAP financial measures are provided to enhance readers' overall
understanding of our current financial results and to provide further
information for comparative purposes. Management believes the non-GAAP
financial measures provide useful information to management and investors
by isolating certain expenses, gains, and losses that may not be
indicative of our core operating results and business outlook.
Specifically, the non-GAAP financial measures include non-GAAP adjusted
loss, and its presentation is intended to help the reader understand the
effect of the loss on the issuance or modification of convertible
securities, the periodic change in fair value of convertible securities,
the loss on debt extinguishment and the corresponding accounting for
non-cash charges on financial performance. In addition, management
believes non-GAAP financial measures enhance the comparability of results
against prior periods.
-- A reconciliation to the most directly comparable GAAP measure of all
non-GAAP financial measures included in this press release for the three
and nine months ended September 30, 2026 and 2025 are as follows:
For the three months ended For the nine months ended
September 30, September 30,
2026 2025 2026 2025
-------------- --------------- -------------- --------------
(in thousands
except per-share
amounts)
Revenue $ 41 $ 5 $ 96 $ 19
Operating expenses 6,768 4,849 21,879 15,022
Other (Income)
Expense, net 6,308 1,167 (1,087) (15,291)
-------------- --------------- -------------- --------------
Net (Income) Loss 13,035 6,011 20,696 (288)
-------------- --------------- -------------- --------------
Net income (loss)
attributable to
common
stockholders (11,752) (6,328) (24,219) (1,942)
Preferred Stock
dividends and
deemed dividends 97 945 7,120 3,606
-------------- --------------- -------------- --------------
Net income (loss)
as reported (11,655) (5,383) (17,099) 1,664
Adjustments:
Depreciation and
amortization
expense(1) 19 22 58 87
Interest expense,
net(2) (2) (2) (26) (8)
NCI ownership share
of Interest and
Depreciation
adjustments (268) -- (775) --
-------------- --------------- -------------- --------------
EBITDA (11,906) (5,363) (17,842) 1,743
Other non-cash or
financing related
expenses:
Stock-based
compensation
expense(3) 967 383 2,065 1,475
Operating expenses
issued in
stock(1) 140 52 2,091 155
Change in FV equity
method
investments 9,985 4,382 10,612 (5,979)
Preliminary Change
in FV convertible
debt(2) (330) 100 (3,126) 349
Loss on debt
extinguishment(2) -- -- 3,422 58
Change in fair
value -- warrant
liability -- -- (1,831) --
Change in fair
value -- rights
liability (96) -- (150) --
-------------- --------------- -------------- --------------
Non-GAAP adjusted
(loss) $ (1,240) $ (446) $ (4,759) $ (2,199)
============== =============== ============== ==============
Non-GAAP shares
outstanding, basic
and diluted 6,640 718 4,849 596
Non-GAAP adjusted
(loss) income per
share, basic and
diluted $ (0.19) $ (0.62) $ (0.98) $ (3.69)
(1) Included in general and administrative expenses in the financial
statements.
(2) Included in other income and expenses.
(3) Stock-based compensation ("SBC") expense is included in operating expenses
and is detailed as follows in the table below by category within operating
expenses for the non- GAAP Net operating expenses:
(in thousands
except per-share For the three months ended For the nine months ended
amounts) September 30, September 30,
2026 2025 2026 2025
-------------- -------------- -------------- --------------
Cost of revenue $ 158 $ 55 $ 377 $ 133
Stock-based
compensation
expense(3) -- -- -- --
-------------- -------------- -------------- --------------
Net cost of
revenue 158 55 377 133
============== ============== ============== ==============
Sales and
marketing 206 201 636 668
Stock-based
compensation
expense(3) (17) (13) (30) (59)
-------------- -------------- -------------- --------------
Net sales and
marketing 189 188 606 609
============== ============== ============== ==============
General and
administrative 4,482 3,505 15,489 11,557
Depreciation
expense (19) (22) (58) (87)
Operating
expenses issued
in stock (140) (52) (2,091) (155)
Stock-based
compensation
expense(3) (899) (332) (1,927) (1,276)
-------------- -------------- -------------- --------------
Net general and
administrative 3,424 3,099 11,413 10,039
============== ============== ============== ==============
Research and
development 1,922 1,088 5,377 2,664
Stock-based
compensation
expense(3) (51) (38) (108) (140)
-------------- -------------- -------------- --------------
Net research and
development 1,871 1,050 5,269 2,524
============== ============== ============== ==============
Total operating
expenses 6,768 4,849 21,879 15,022
Depreciation and
amortization
expense (19) (22) (58) (87)
Operating
expenses issued
in stock (140) (52) (2,091) (155)
Stock-based
compensation
expense(3) (967) (383) (2,065) (1,475)
-------------- -------------- -------------- --------------
Net operating
expenses $ 5,642 $ 4,392 $ 17,665 $ 13,305
============== ============== ============== ==============
About PAVmed and its Subsidiaries
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard(R) Esophageal DNA Test and EsoCheck(R) Esophageal Cell Collection Device--the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
For more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-preliminary-third-quarter-2026-financial-results-302938900.html
SOURCE PAVmed Inc.